Experience MedEx Seamless Care Delivery — 10% OFF on Your First Appointment - Use 'TRYMEDEX' Coupon Code on Checkout //////////////////////////////////// General Price List — Consultation: 750 THB | Home Lab Test Service Fee: 750 THB (FREE for Orders Over 5,000 THB)
MedEx is a one-stop destination when it comes to medical tourism and digital specialized health care services. MedEx serves as a connector between patients and trusted world-class health service providers.
Genetic and carrier screening guide · 2026
Thalassaemia carriage is common enough in Thailand that screening is a routine part of preconception and antenatal care — and it is not covered by NIPT.
Thalassaemia is a group of inherited haemoglobin disorders, and carriage is common across Southeast Asia including Thailand, where a substantial proportion of the population carries alpha thalassaemia, beta thalassaemia or haemoglobin E. Carriers are usually healthy, but when both partners are carriers of compatible types there is a risk of a severely affected pregnancy. Screening starts with a full blood count looking at MCV and MCH, adds DCIP for haemoglobin E and haemoglobin typing, and proceeds to DNA analysis where indicated. NIPT does not screen for thalassaemia.
| Why it matters here | Carriage of alpha, beta thalassaemia or haemoglobin E is common in Thailand |
|---|---|
| First step | Full blood count — low MCV or MCH raises suspicion |
| Second step | DCIP screening for haemoglobin E, and haemoglobin typing (HPLC or electrophoresis) |
| Definitive | DNA analysis, particularly for alpha thalassaemia |
| Not covered by NIPT | Thalassaemia is a single-gene condition, outside any NIPT panel |
| Price | Listed on the MedEx NIPT service page; confirm before booking as panels differ |
Thalassaemia carriage is common throughout Southeast Asia, and Thailand has one of the higher carrier frequencies globally, with alpha thalassaemia, beta thalassaemia and haemoglobin E all present in the population. Because carriers are typically healthy, most do not know.
The consequence is real. When both partners carry compatible variants, each pregnancy may carry a significant risk of a severely affected child. The most serious outcomes include Hb Bart’s hydrops fetalis, which is incompatible with life and carries maternal risks, and beta thalassaemia major and severe beta thalassaemia/HbE disease, which involve lifelong transfusion dependence or transplantation.
Thailand operates a national thalassaemia prevention and control programme for this reason, and screening is a routine part of antenatal care. If you are planning a pregnancy, screening before conception gives the widest range of options.
| Step 1: Full blood count | A low MCV or MCH raises suspicion. Iron deficiency also lowers these, so ferritin is usually checked alongside — and the two can coexist. |
|---|---|
| Step 2: DCIP test | A screening test for haemoglobin E, which is common in Thailand and is central to the risk of severe beta thalassaemia/HbE disease. |
| Step 3: Haemoglobin typing | HPLC or electrophoresis identifies abnormal haemoglobins and quantifies HbA2 and HbF, which identifies beta thalassaemia trait. |
| Step 4: DNA analysis | Definitive identification of specific mutations, particularly important for alpha thalassaemia, where haemoglobin typing is often normal in carriers. |
| Step 5: Partner testing | Essential. Risk depends on the combination, not on either result alone. |
Steps 1 to 3 can run from a single blood draw. Arrange through the MedEx lab test catalogue or search individual tests in the lab directory.
Screening starts with a full blood count — a single draw covers the first steps.
An important limitation worth understanding: haemoglobin typing is frequently normal in alpha thalassaemia carriers. Someone can have a low MCV, a normal haemoglobin typing result, and still carry a clinically significant alpha thalassaemia deletion.
This matters because the most severe outcome — Hb Bart’s hydrops fetalis — arises from alpha thalassaemia, specifically when both partners carry the alpha-thalassaemia-1 (Southeast Asian) deletion. That deletion is precisely the one most likely to be missed by haemoglobin typing alone.
So if the full blood count shows a low MCV or MCH and iron deficiency has been excluded, DNA analysis should be pursued even when haemoglobin typing is normal. This is a common gap, and it is worth asking about explicitly. See MedEx genetic testing services.
Being a carrier couple does not mean a child will be affected, and the level of risk depends entirely on which variants are involved. Genetic counselling is the essential step here, because the combinations differ enormously in consequence.
Options generally discussed include:
Note that Hb Bart’s hydrops carries maternal risks including severe pre-eclampsia, so early identification matters for the mother as well as the pregnancy.
Screening before conception rather than during pregnancy widens the options considerably. Book a specialist teleconsultation or a doctor consultation to work through it, and see the prenatal testing pathway guide for how this fits alongside NIPT and ultrasound.
No. Thalassaemia is a single-gene condition and falls outside any NIPT panel. It requires separate carrier screening, starting with a full blood count.
A full blood count first, looking at MCV and MCH, with ferritin to exclude iron deficiency. Then DCIP screening for haemoglobin E and haemoglobin typing, and DNA analysis where indicated.
Yes, frequently. Haemoglobin typing is often normal in alpha thalassaemia carriers, so DNA analysis should be pursued where MCV or MCH is low and iron deficiency has been excluded.
Yes. Risk to a pregnancy depends on the combination of both partners’ variants, not on either result alone.
It does not mean a child will be affected, and the level of risk depends on which variants are involved. Genetic counselling is essential, and options include prenatal diagnosis, preimplantation genetic testing and informed monitoring.
Before conception where possible, since that gives the widest range of options. Screening is also a routine part of antenatal care in Thailand.
Both partners need testing. Risk depends on the combination.
Medical disclaimer: This article is general health information and does not replace medical advice, diagnosis or treatment. Laboratory reference ranges differ between laboratories and results must be interpreted alongside your symptoms, medicines and medical history. Speak with a qualified clinician before starting, stopping or changing any treatment. Service details, inclusions and prices can change — confirm them with MedEx before booking.
When to draw estradiol, why the day of the cycle changes everything, what it adds in menopause assessment and how it is used in men.
Why NIPT starts at 10 weeks, how gestational age affects fetal fraction, and how to plan timing around the dating scan and confirmatory options.
Why Ureaplasma parvum, U. urealyticum and Mycoplasma hominis are usually normal flora, what a positive result means and when treatment is justified.
Find quality services, specialists, procedures and more from the comfort of your home. All you need to do is enter a keyword or phrase describing what you are looking for.
DOWNLOAD MEDEX ONE APP
MedEx is a one-stop digital care navigation concierge backed by physical infrastructure, owning the patient experience and decentralizing the care continuum across Asia—integrating provider aggregation, satellite clinics, telemedicine, and at-home care.
MedEx is a one-stop digital care navigation concierge backed by physical infrastructure, owning the patient experience and decentralizing the care continuum across Asia—integrating provider aggregation, satellite clinics, telemedicine, and at-home care.
© 2020-26 MedEx Ventures Co., Ltd.
